CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Listed Company

CRLCIK 0001100682NYSELarge AcceleratedServices-Commercial Physical & Biological ResearchFY ends Dec 27

Period

FY 2025

Revenue

$4.02B

Net Income

$-144.34M

Total Assets

$7.14B

Equity

$3.16B

Shares Out

49.23M

Op. Cash Flow

$737.65M

Business

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. is a global non-clinical drug development partner that supports discovery through non-clinical development and manufacturing for biopharmaceutical, biotechnology, academic, government and industrial clients. It offers research models and related services, discovery and safety assessment services (including toxicology, pathology, bioanalysis and pharmacokinetics), and manufacturing solutions (microbial detection/identification and biologics testing and CDMO services). The company reports three segments—Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Solutions. Its operations span a worldwide network of sites serving clients principally through direct sales, key account management, digital platforms and selected distributors across North America, Europe, Asia and other regions.

Summary from filing dated 2025-02-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	4,015	4,050	4,129	3,976	3,540
Selling, general and administrative	743	751	748	665	620
Amortization of intangible assets	179	139	137	147	125
Intangible asset impairment	211	0	0	—	—
Goodwill impairment	165	215	0	0	—
Operating income	25	227	617	651	590
Interest income	5	9	5	780,000	652,000
Interest expense	−107	−126	−137	−59	—
Other income (expense), net	−23	−17	96	31	−36
Income (loss) before income taxes	−100	93	581	623	481
Provision for income taxes	43	68	101	130	82
Net income (loss)	−142	25	480	493	399
Less: Net income attributable to noncontrolling interests	2	3	6	6	8
Net income (loss) attributable to Charles River Laboratories International, Inc.	−144	22	475	486	391
Less: Incremental dividends attributed to noncontrolling interest holders	0	12	0	0	—
Net income (loss) available to Charles River Laboratories International, Inc. common shareholders	−144	10	475	486	—
Basic (in dollars per share)	−2.91	0.2	9.27	9.57	7.77
Diluted (in dollars per share)	−2.91	0.2	9.22	9.48	7.6
Basic (in shares)	50	51	51	51	50
Diluted (in shares)	50	52	51	51	51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	214	195	277	234	241
Trade receivables and contract assets, net of allowances for credit losses of $10,463 and $18,301, respectively	709	721	780	752	643
Inventories	299	279	380	256	199
Prepaid assets	96	103	88	89	94
Other current assets	129	106	83	108	97
Total current assets	1,447	1,403	1,609	1,439	1,274
Property, plant and equipment, net	1,655	1,604	1,640	1,466	1,291
Venture capital and strategic equity investments	207	218	244	312	201
Operating lease right-of-use assets, net	361	412	394	392	293
Goodwill	2,764	2,847	3,095	2,850	2,712
Intangible assets, net	340	723	864	955	1,061
Deferred tax assets	67	42	40	41	40
Other assets	293	278	309	148	152
Total assets	7,135	7,528	8,195	7,603	7,024
Accounts payable	149	140	169	206	198
Accrued compensation	269	179	213	197	246
Deferred revenue	210	248	242	264	220
Accrued liabilities	270	232	228	220	229
Other current liabilities	222	194	203	205	140
Total current liabilities	1,120	994	1,055	1,092	1,033
Long-term debt, net and finance leases	2,136	2,240	2,647	2,708	2,664
Operating lease right-of-use liabilities	434	484	419	390	253
Deferred tax liabilities	95	107	191	216	240
Other long-term liabilities	138	195	223	175	243
Total liabilities	3,924	4,020	4,536	4,579	4,432
Commitments and contingencies (Notes 2, 11, 13, and 18)	—	—	—	—	—
Redeemable noncontrolling interests	41	41	57	42	53
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0	0	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 49,217 shares issued and outstanding as of December 27, 2025 and 51,141 shares issued and outstanding as of December 28, 2024	492,000	511,000	513,000	509,000	505,000
Additional paid-in capital	1,947	1,966	1,906	1,805	1,718
Retained earnings	1,389	1,812	1,887	1,433	981
Treasury stock, at cost, zero shares as of December 27, 2025 and December 28, 2024	0	0	0	0	0
Accumulated other comprehensive loss	−172	−317	−196	−262	−165
Total Charles River Laboratories International, Inc. equity	3,165	3,462	3,597	2,976	2,535
Nonredeemable noncontrolling interest	5	5	5	5	4
Total equity	3,170	3,467	3,602	2,981	2,539
Total liabilities, redeemable noncontrolling interests and equity	7,135	7,528	8,195	7,603	7,024

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	403	362	314	304	266
Long-lived asset impairments	259	52	42	6	733,000
Stock-based compensation	71	70	72	74	71
Deferred income taxes	−75	−67	−51	−36	−24
Write down of inventories	12	47	6	6	—
(Gains) losses and impairments on venture capital and strategic equity investments, net	25	13	−98	—	—
Provision for credit losses	6	15	18	7	2
(Gain) loss on divestitures, net	−3	659,000	961,000	−123	−25
Other, net	3	33	1	16	3
Trade receivables and contract assets, net	36	22	−33	−151	−27
Inventories	−49	17	−62	−79	−25
Accounts payable	3	−14	−20	−3	45
Accrued compensation	79	−28	12	−42	44
Deferred revenue	−38	19	−22	58	−13
Customer contract deposits	15	7	−16	30	17
Other assets and liabilities, net	−32	−52	39	33	2
Net cash provided by operating activities	738	735	684	620	761
Capital expenditures	−219	−233	−319	−325	−229
Purchases of investments and contributions to venture capital investments	−20	−53	−54	−158	−46
Acquisition of businesses and assets, net of cash acquired	0	−5	−195	−283	−1,293
Proceeds from sale of investments	9	42	7	5	7
Proceeds from sale of businesses, net	17	0	0	—	—
Other, net	3	5	−2	−9	264,000
Net cash used in investing activities	−209	−245	−563	−608	−1,438
Proceeds from long-term debt and revolving credit facility	1,228	1,082	776	2,952	6,951
Payments on long-term debt, revolving credit facility, and finance lease obligations	−1,349	−1,494	−852	−2,933	−6,243
Proceeds from exercises of stock options	714,000	24	26	25	46
Purchase of treasury stock	−361	−119	−24	−39	−41
Payments of contingent consideration	−22	0	−3	−10	−2
Purchase of remaining equity interests of other redeemable noncontrolling interest	−19	−12	−5	−31	0
Other, net	−14	−31	−4	−8	0
Net cash used in financing activities	−537	−551	−86	−42	673
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	19	−17	8	26	18
Net change in cash, cash equivalents, and restricted cash	10	−79	43	−5	13

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro